

**Supplemental Table 2.** TFV plasma pharmacokinetic parameter estimates within groups, by route of hormone administration and spironolactone use

	<b>C<sub>tau</sub></b> <b>(ng/mL)</b>	<b>C<sub>max</sub></b> <b>(ng/mL)</b>	<b>T<sub>max</sub></b> <b>(hrs)</b>	<b>AUC<sub>tau</sub></b> <b>(ng*hr/mL)</b>	<b>T<sub>1/2</sub></b> <b>(hrs)</b>
<b>ROUTE OF ESTRADIOL ADMINISTRATION IN TW (N=26)</b>					
PO/SL	52.9 (38.0, 73.6)	327 (266, 404)	1.11 (0.96, 1.28)	2530 (1962, 3263)	16.7 (13.6, 20.5)
IM	60.5 (52.5, 69.7)	298 (265, 336)	1.26 (0.95, 1.68)	2820 (2511, 3166)	15.2 (14.1, 16.3)
PO/SL vs. IM, GMR (95% CI)	0.87 (0.61, 1.26)	1.10 (0.86, 1.39)	0.88 (0.66, 1.17)	0.90 (0.68, 1.19)	1.10 (0.88, 1.38)
P-value	0.450	0.431	0.360	0.435	0.371
<b>ROUTE OF TESTOSTERONE ADMINISTRATION IN TM (N=24)</b>					
SQ	62.6 (50.7, 77.2)	280 (207, 380)	1.18 (0.89, 1.56)	2881 (2320, 3577)	15.5 (14.0, 17.2)
IM	60.5 (52.6, 69.6)	310 (259, 372)	1.26 (1.02, 1.57)	2778 (2376, 3247)	16.3 (15.0, 17.7)
SQ vs. IM, GMR (95% CI)	1.03 (0.82, 1.31)	0.90 (0.65, 1.26)	0.93 (0.67, 1.30)	1.04 (0.81, 1.34)	0.95 (0.84, 1.08)
P-value	0.772	0.536	0.659	0.767	0.405
<b>SPIRONOLACTONE USE IN TW (N=26)</b>					
Spironolactone	48.5 (30.9, 76.3)	275 (208, 363)	1.30 (0.96, 1.75)	2361 (1613, 3455)	14.4 (12.6, 16.3)
No spironolactone	60.1 (49.4, 73.0)	333 (292, 379)	1.13 (0.95, 1.35)	2804 (2438, 3226)	16.8 (14.4, 19.5)
Use vs. no use, GMR (95% CI)	0.81 (0.55, 1.19)	0.83 (0.64, 1.06)	1.15 (0.84, 1.57)	0.84 (0.62, 1.14)	0.86 (0.68, 1.08)
P-value	0.266	0.125	0.375	0.247	0.185